home / stock / itci / itci quote
Last: | $67.24 |
---|---|
Change Percent: | -0.56% |
Open: | $66.02 |
Close: | $67.24 |
High: | $67.7 |
Low: | $65.81 |
Volume: | 985,317 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$67.24 | $66.02 | $67.24 | $67.7 | $65.81 | 985,317 | 05-31-2024 |
$65.65 | $66.66 | $65.65 | $67.4 | $65.15 | 592,404 | 05-30-2024 |
$66.54 | $65.06 | $66.54 | $67.09 | $64.72 | 766,722 | 05-29-2024 |
$65.62 | $65.67 | $65.62 | $66.55 | $65.2 | 633,790 | 05-28-2024 |
$65.54 | $66.48 | $65.54 | $66.48 | $64.88 | 628,393 | 05-27-2024 |
$65.54 | $66.48 | $65.54 | $66.48 | $64.88 | 628,393 | 05-24-2024 |
$66.37 | $70 | $66.37 | $70 | $65.82 | 913,664 | 05-23-2024 |
$67.3 | $66.88 | $67.3 | $69.12 | $66.86 | 812,207 | 05-22-2024 |
$67 | $65.1 | $67 | $67.99 | $64.89 | 1,007,526 | 05-21-2024 |
$65.32 | $65.06 | $65.32 | $65.82 | $64.09 | 999,099 | 05-20-2024 |
$65 | $66.88 | $65 | $66.88 | $64.92 | 783,425 | 05-17-2024 |
$66.53 | $66.72 | $66.53 | $67.095 | $65.51 | 723,533 | 05-16-2024 |
$66.84 | $66.68 | $66.84 | $68.16 | $66.51 | 691,551 | 05-15-2024 |
$65.71 | $66.76 | $65.71 | $67.27 | $65.17 | 696,954 | 05-14-2024 |
$66.32 | $65.16 | $66.32 | $67.22 | $65.16 | 706,863 | 05-13-2024 |
$64.96 | $65.75 | $64.96 | $66.71 | $64.92 | 730,757 | 05-10-2024 |
$65.56 | $66.97 | $65.56 | $67.23 | $65.45 | 767,145 | 05-09-2024 |
$67 | $71.12 | $67 | $71.22 | $66.95 | 977,604 | 05-08-2024 |
$71.21 | $69.72 | $71.21 | $71.635 | $68.61 | 1,128,033 | 05-07-2024 |
$71.01 | $68.88 | $71.01 | $71.02 | $68.26 | 749,036 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Intra-Cellular Therapies Inc. Company Name:
ITCI Stock Symbol:
NASDAQ Market:
Intra-Cellular Therapies Inc. Website:
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development ...
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and ...